A Study on Diabetic Patients Related To Functions of Fibroblast Growth Factor-23 on Bone Metabolism

被引:0
|
作者
Suwalka, Abhilasha [1 ,2 ]
Sharma, Balram [3 ]
Prabhakar, Pranav Kumar [4 ]
机构
[1] SMS Med Coll & Attached Hosp, Dept Med Lab Sci, LPU Phagwara Punjab, JLN Marg, Jaipur 302004, Rajasthan, India
[2] SMS Med Coll & Attached Hosp, Dept Endocrinol, JLN Marg, Jaipur 302004, Rajasthan, India
[3] SMS Med Coll & Attached Hosp, Dept Endocrinol, Jaipur 302004, Rajasthan, India
[4] LPU Phagwara, Dept Med Lab Sci, Punjab 144411, India
关键词
Diabetes Mellitus; FGF-23; Bone remodeling; Controls; Pre-diabetes; Bio-marker; VITAMIN-D; STRUCTURAL BASIS; FRACTURE RISK; FGF23; SUPPLEMENTATION; METAANALYSIS; SPECIFICITY; INSULIN; COHORT; FGF-23;
D O I
10.47750/pnr.2022.13.S05.160
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim/Purpose:-Type 2 Diabetes Mellitus affecting around major population around the world and with increasing ratio in near future. There is modification in tissue cells which fails to respond to insulin properly.(FGF-23) Fibroblast Growth Factor-23 known as a hormone composed of peptides circulating in blood synthesized by (osteoblast) bone cells. FGF-23 can exhibit physiological functions in conjugation to bone metabolism like bone calcification and hematopoiesis.An important nutrient of osteoblast cells has been a glucose and also many studies have shown significant alteration of bone formation in increased glucose level. Hyperglycemia affects bone remodeling in cells of bones, insulin signalinginteraction and metabolism of bones through insulin receptors directly or indirectly. Hence, this study is designed to estimate levels of FGF-23 in bone metabolism among healthy group, prediabetic and in people suffering from type-2 diabetes mellitus.Methods:-The type of present study is observational and is designed as a case control study performed in hospital. Total of 225 volunteers were taken in control group, prediabetes and 75 diabetes mellitus type 2patients. Standard deviation and was analyzed using one-way ANOVA test and for further analysis for specific differences between 3 groups with post-hoc tukey test. Values of P<0.05 was taken as significant.Results:-Our results shows positive relationship for the parameters tested when found between the groups using test known as post -hoc tukey (p<0.001).Conclusion:-The present study gives clear insight about bone remodeling and bone formation when controlled by FGF-23 hormone and can be predicted as biological possible bio-marker in the bone metabolism. Henceforth, more advanced studies are required for detailed examination of FGF-23 physiological actions on bone metabolism and its inter-relationship with insulin resistance especially diabetic patients.
引用
收藏
页码:1008 / 1022
页数:15
相关论文
共 50 条
  • [1] Fibroblast Growth Factor-23 and Phosphorus Metabolism
    Tiosano, Dov
    [J]. CARTILAGE AND BONE DEVELOPMENT AND ITS DISORDERS, 2011, 21 : 67 - 77
  • [2] Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis
    Fumiko Kojima
    Keiko Uchida
    Tetsuya Ogawa
    Yoshiko Tanaka
    Kosaku Nitta
    [J]. International Urology and Nephrology, 2008, 40 : 1067 - 1074
  • [3] Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis
    Kojima, Fumiko
    Uchida, Keiko
    Ogawa, Tetsuya
    Tanaka, Yoshiko
    Nitta, Kosaku
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2008, 40 (04) : 1067 - 1074
  • [4] THE ASSOCIATION OF FIBROBLAST GROWTH FACTOR-23 AND BONE TURNOVER MARKERS ON HEMODIALYSIS PATIENTS
    Wu, Ping-Hsun
    Lin, Yi-Ting
    Kuo, Mei-Chuan
    Chiu, Yi-Wen
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [5] FIBROBLAST GROWTH FACTOR-23 IS RELATED WITH BONE MINERAL CONTENT OF END STAGE RENAL DISEASE PATIENTS ON HAEMODIALYSIS
    Hasuike, Yukiko
    Fukao, Wataru
    Kida, Aritoshi
    Yorifuji, Soshi
    Mizusaki, Kosuke
    Yahiro, Mana
    Nanami, Masayoshi
    Nagasawa, Yasuyuki
    Kuragano, Takahiro
    Nakanishi, Takeshi
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 245 - 245
  • [6] Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy
    Burcu Dogan
    Izzet Hakki Arikan
    Derya Guler
    Nursen Keles
    Banu Isbilen
    Ferruh Isman
    Aytekin Oguz
    [J]. International Urology and Nephrology, 2016, 48 : 399 - 407
  • [7] Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy
    Dogan, Burcu
    Arikan, Izzet Hakki
    Guler, Derya
    Keles, Nursen
    Isbilen, Banu
    Isman, Ferruh
    Oguz, Aytekin
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (03) : 399 - 407
  • [8] METABOLIC BONE DISEASE, ATHEROSCLEROSIS AND FIBROBLAST GROWTH FACTOR-23 IN PERITONEAL DIALYSIS PATIENTS
    Akalin, Nilgul
    Akalin, Nilgul
    Altiparmak, Mehmet Riza
    Trabulus, Sinan
    Yalin, Aye Serap
    Seyahi, Nurhan
    Ataman, Rezzan
    Serdengeti, Kamil
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 154 - 154
  • [9] Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy
    Westerberg, Per-Anton
    Ljunggren, Osten
    Larsson, Tobias E.
    Wadstrom, Jonas
    Linde, Torbjorn
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (12) : 4068 - 4071
  • [10] Fibroblast Growth Factor-23 importance as a prognostic factor in hemodialysis patients
    Al Atbee, Mohammed Younus Naji
    Hamu, Ali Hussein
    Hammoudi, Faten Abdulghani
    Allawi, Ali Abdulmajid Dyab
    Tuama, Hala Sami
    [J]. REVISTA LATINOAMERICANA DE HIPERTENSION, 2023, 18 (09): : 423 - 431